Literature DB >> 24932923

Accelerator mass spectrometry detection of beryllium ions in the antigen processing and presentation pathway.

Brian C Tooker1, Stephen M Brindley, Marina L Chiarappa-Zucca, Kenneth W Turteltaub, Lee S Newman.   

Abstract

Exposure to small amounts of beryllium (Be) can result in beryllium sensitization and progression to Chronic Beryllium Disease (CBD). In CBD, beryllium is presented to Be-responsive T-cells by professional antigen-presenting cells (APC). This presentation drives T-cell proliferation and pro-inflammatory cytokine (IL-2, TNFα, and IFNγ) production and leads to granuloma formation. The mechanism by which beryllium enters an APC and is processed to become part of the beryllium antigen complex has not yet been elucidated. Developing techniques for beryllium detection with enough sensitivity has presented a barrier to further investigation. The objective of this study was to demonstrate that Accelerator Mass Spectrometry (AMS) is sensitive enough to quantify the amount of beryllium presented by APC to stimulate Be-responsive T-cells. To achieve this goal, APC - which may or may not stimulate Be-responsive T-cells - were cultured with Be-ferritin. Then, by utilizing AMS, the amount of beryllium processed for presentation was determined. Further, IFNγ intracellular cytokine assays were performed to demonstrate that Be-ferritin (at levels used in the experiments) could stimulate Be-responsive T-cells when presented by an APC of the correct HLA type (HLA-DP0201). The results indicated that Be-responsive T-cells expressed IFNγ only when APC with the correct HLA type were able to process Be for presentation. Utilizing AMS, it was determined that APC with HLA-DP0201 had membrane fractions containing 0.17-0.59 ng Be and APC with HLA-DP0401 had membrane fractions bearing 0.40-0.45 ng Be. However, HLA-DP0401 APC had 20-times more Be associated with the whole cells (57.68-61.12 ng) than HLA-DP0201 APC (0.90-3.49 ng). As these findings demonstrate, AMS detection of picogram levels of Be processed by APC is possible. Further, regardless of form, Be requires processing by APC to successfully stimulate Be-responsive T-cells to generate IFNγ.

Entities:  

Keywords:  Accelerator mass spectrometry (AMS); beryllium; chronic beryllium disease; metal antigen; metal processing

Mesh:

Substances:

Year:  2014        PMID: 24932923      PMCID: PMC4426990          DOI: 10.3109/1547691X.2014.917748

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN: 1547-691X            Impact factor:   3.000


  21 in total

1.  A case control etiologic study of sarcoidosis: environmental and occupational risk factors.

Authors:  Lee S Newman; Cecile S Rose; Eddy A Bresnitz; Milton D Rossman; Juliana Barnard; Margaret Frederick; Michael L Terrin; Steven E Weinberger; David R Moller; Geoffrey McLennan; Gary Hunninghake; Louis DePalo; Robert P Baughman; Michael C Iannuzzi; Marc A Judson; Genell L Knatterud; Bruce W Thompson; Alvin S Teirstein; Henry Yeager; Carol J Johns; David L Rabin; Benjamin A Rybicki; Reuben Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2004-09-03       Impact factor: 21.405

2.  Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response.

Authors:  Andrew P Fontenot; Brent E Palmer; Andrew K Sullivan; Fenneke G Joslin; Cara C Wilson; Lisa A Maier; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2005-09-08       Impact factor: 14.808

3.  Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells.

Authors:  Andrew P Fontenot; Timothy S Keizer; Mark McCleskey; Douglas G Mack; Roberto Meza-Romero; Jianya Huan; David M Edwards; Yuan K Chou; Arthur A Vandenbark; Brian Scott; Gregory G Burrows
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

4.  Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.

Authors:  A P Fontenot; M Torres; W H Marshall; L S Newman; B L Kotzin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

5.  Beryllium induces IL-2 and IFN-gamma in berylliosis.

Authors:  S S Tinkle; L A Kittle; B A Schumacher; L S Newman
Journal:  J Immunol       Date:  1997-01-01       Impact factor: 5.422

6.  Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease.

Authors:  Richard T Sawyer; Brian J Day; Valerie A Fadok; Marina Chiarappa-Zucca; Lisa A Maier; Andrew P Fontenot; Lori Silveira; Lee S Newman
Journal:  Am J Respir Cell Mol Biol       Date:  2004-07-15       Impact factor: 6.914

7.  Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP.

Authors:  Richard T Sawyer; Charles E Parsons; Andrew P Fontenot; Lisa A Maier; May M Gillespie; E Brigitte Gottschall; Lori Silveira; Lee S Newman
Journal:  Am J Respir Cell Mol Biol       Date:  2004-02-19       Impact factor: 6.914

8.  Beryllium exposure and chronic beryllium disease.

Authors:  Peter F Infante; Lee S Newman
Journal:  Lancet       Date:  2004-02-07       Impact factor: 79.321

9.  Components of the ligand for a Ni++ reactive human T cell clone.

Authors:  Linh Lu; Jörg Vollmer; Corinne Moulon; Hans Ulrich Weltzien; Philippa Marrack; John Kappler
Journal:  J Exp Med       Date:  2003-03-03       Impact factor: 14.307

10.  Graphite furnace atomic absorption spectrometry as a routine method for the quantification of beryllium in blood and serum.

Authors:  Chadi H Stephan; Michel Fournier; Pauline Brousseau; Sébastien Sauvé
Journal:  Chem Cent J       Date:  2008-07-02       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.